Video

Dr. Julio Pow-Sang on Options for Low-and Intermediate-Risk Prostate Cancer

Julio Pow-Sang, MD, chair of Urological Oncology at Moffitt Cancer Center, discusses the grey zone between low and intermediate risk in prostate cancer.

There is an overlap between low and intermediate-risk classification. At present, one of the main options for low-risk patients is to do active surveillance, says Pow-Sang.

Testing to determine low-risk was very rudimentary, he says. There was an approximately 30% chance that, with further testing, the patient was actually determined to be intermediate-risk. That was significant because intermediate-risk patients are recommended treatment, while low-risk patients are recommended active surveillance.

Newer tests and a better understanding of the behavior of the cancer have helped determine who those men are versus the ones who might need treatment, says Pow-Sang.

Related Videos
Roxana S. Dronca, MD, discusses the FDA’s approval of subcutaneous nivolumab across solid tumor indications.
Craig Eckfeldt, MD
Whitney Goldsberry, MD
Jonathan Wesley Riess, MD, MS, an associate professor at the University of California (UC) Davis
Yair Lotan, MD, professor, urology, chief, urologic oncology, Jane and John Justin Distinguished Chair in Urology, UT Southwestern Harold C. Simmons Comprehensive Cancer Center; medical director, Urology Clinic, UT Southwestern and Parkland Health and Hospital System
Laura A. Huppert, MD
Polly Niravath, MD
Arvind N. Dasari, MD, MS
Charles E. Geyer, Jr., MD
Sattva S. Neelapu, MD